Home
EXEL
EXEL News

Latest Exelixis Inc. (EXEL) News on September 17, 2025

MT Newswires

21 hours ago

Adagene Expands Agreement With Exelixis For SAFEbody Technology Platform; Adagene Shares Up Pre-Bell

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

GlobeNewswire

21 hours ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

9 days ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D

Insider Monkey

11 days ago

Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D

Exelixis, Inc. (EXEL): A Bull Case Theory

Insider Monkey

12 days ago

Exelixis, Inc. (EXEL): A Bull Case Theory

Is Exelixis Still Attractive After Recent 13% Pullback and Strong Cash Flow Growth?

Simply Wall St.

a month ago

Is Exelixis Still Attractive After Recent 13% Pullback and Strong Cash Flow Growth?

Will EXEL's Share Repurchase Program Boost Value for Investors?

Zacks

a month ago

Will EXEL's Share Repurchase Program Boost Value for Investors?

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Zacks

2 months ago

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

Zacks

2 months ago

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

2 Stocks to Buy With Less Than $50

Motley Fool

2 months ago

2 Stocks to Buy With Less Than $50

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Zacks

2 months ago

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

Zacks

2 months ago

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

What's Fueling Tempus AI's Explosive Sales Growth?

Zacks

2 months ago

What's Fueling Tempus AI's Explosive Sales Growth?

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

Zacks

3 months ago

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

Zacks

3 months ago

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

Stephens Upgrades Exelixis (EXEL) Stock, Raises PT

Insider Monkey

3 months ago

Stephens Upgrades Exelixis (EXEL) Stock, Raises PT

Exelixis (NasdaqGS:EXEL) Reports Positive Phase 3 Trial Results For Colorectal Cancer

Simply Wall St.

3 months ago

Exelixis (NasdaqGS:EXEL) Reports Positive Phase 3 Trial Results For Colorectal Cancer

3 Reasons Growth Investors Will Love Exelixis (EXEL)

Zacks

3 months ago

3 Reasons Growth Investors Will Love Exelixis (EXEL)

The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis

Zacks

3 months ago

The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis

23 Stocks That Score High on What Counts in the 2025 Market

Barrons.com

3 months ago

23 Stocks That Score High on What Counts in the 2025 Market

Argus Research

3 months ago

EXEL: Raising target price to $50.00

Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?

Zacks

3 months ago

Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

EXEL Stock Rises on Positive Data From Colorectal Cancer Study

Zacks

3 months ago

EXEL Stock Rises on Positive Data From Colorectal Cancer Study

Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?

Zacks

3 months ago

Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?

Exploring US High Growth Tech Stocks To Watch In June 2025

Simply Wall St.

3 months ago

Exploring US High Growth Tech Stocks To Watch In June 2025

Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2

Zacks

3 months ago

Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2

MT Newswires

3 months ago

Stephens Upgrades Exelixis to Overweight From Equalweight, Adjusts Price Target to $60 From $29

Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug

Investor's Business Daily

3 months ago

Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Late Afternoon

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed in Afternoon Trading

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug

Investor's Business Daily

3 months ago

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Lower Premarket Monday

MT Newswires

3 months ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Heightened Geopolitical Tensions

MT Newswires

3 months ago

Truist Adjusts Price Target on Exelixis to $55 From $43, Maintains Buy Rating

MT Newswires

3 months ago

Truist Raises Price Target on Exelixis to $55 From $43, Keeps Buy Rating

MT Newswires

3 months ago

Exelixis Says Zanzalintinib, Atezolizumab Combo Improved Survival in Phase 3 Colorectal Cancer Trial

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Business Wire

3 months ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

MT Newswires

3 months ago

Exelixis Says Partner Ipsen Gets EU Panel Backing for Cabometyx to Treat Neuroendocrine Tumors

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

3 months ago

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

Zacks

3 months ago

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Those who invested in Exelixis (NASDAQ:EXEL) three years ago are up 102%

Simply Wall St.

3 months ago

Those who invested in Exelixis (NASDAQ:EXEL) three years ago are up 102%

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Zacks

3 months ago

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis

Zacks

3 months ago

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Zacks

3 months ago

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Can ‘reputational pull’ save biotech from pharma’s image problem?

Pharma Voice

3 months ago

Can ‘reputational pull’ save biotech from pharma’s image problem?

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)

Zacks

3 months ago

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)

Argus Research

3 months ago

EXEL: What does Argus have to say about EXEL?

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Zacks

3 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues

Investor's Business Daily

3 months ago

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues

Kymera Therapeutics Stock Earns 92 RS Rating

Investor's Business Daily

3 months ago

Kymera Therapeutics Stock Earns 92 RS Rating

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

Zacks

3 months ago

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution

Insider Monkey

3 months ago

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

Zacks

3 months ago

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

3 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now

Zacks

4 months ago

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now

2 Top Stocks to Buy With Less Than $100

Motley Fool

4 months ago

2 Top Stocks to Buy With Less Than $100

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

4 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Zacks

4 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?

Zacks

4 months ago

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

4 months ago

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks

4 months ago

EXEL vs. ARGX: Which Stock Is the Better Value Option?

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Zacks

4 months ago

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business

Simply Wall St.

4 months ago

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business

Product Performance, Big Money Lift Exelixis

FX Empire

4 months ago

Product Performance, Big Money Lift Exelixis

MT Newswires

4 months ago

Exelixis Insider Sold Shares Worth $1,515,091, According to a Recent SEC Filing

MT Newswires

4 months ago

Exelixis Reports 'Encouraging' Data in Kidney Cancer Trial

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Business Wire

4 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Business Wire

4 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth

Simply Wall St.

4 months ago

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth

Argus Research

4 months ago

EXEL: Raising target price to $49.00

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Investor's Business Daily

4 months ago

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?

Zacks

4 months ago

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

4 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects

Zacks

4 months ago

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects

MT Newswires

4 months ago

Exelixis Insider Sold Shares Worth $4,600,000, According to a Recent SEC Filing

MT Newswires

4 months ago

Exelixis Insider Sold Shares Worth $1,619,130, According to a Recent SEC Filing

MT Newswires

4 months ago

Exelixis Insider Sold Shares Worth $1,154,500, According to a Recent SEC Filing

MT Newswires

4 months ago

Exelixis Insider Sold Shares Worth $6,488,503, According to a Recent SEC Filing

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Zacks

4 months ago

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Company News for May 15, 2025

Zacks

4 months ago

Company News for May 15, 2025

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

Insider Monkey

4 months ago

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More

Barrons.com

4 months ago

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

Yahoo Finance Video

4 months ago

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

Why Exelixis Stock Is Skyrocketing Today

Motley Fool

4 months ago

Why Exelixis Stock Is Skyrocketing Today

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

Zacks

4 months ago

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Exelixis Inc Earnings Call

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, American Eagle, Exelixis, Grail, and More

Barrons.com

4 months ago

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, American Eagle, Exelixis, Grail, and More

MT Newswires

4 months ago

Morgan Stanley Adjusts Price Target on Exelixis to $47 From $40, Maintains Overweight Rating

Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

4 months ago

Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply

Simply Wall St.

4 months ago

Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

4 months ago

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

Zacks

4 months ago

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

MT Newswires

4 months ago

Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2025 Revenue Outlook Lifted -- Shares Up After Hours

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Zacks

4 months ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

4 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Insider Monkey

4 months ago

Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Share on Social Networks: